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SUMMARY 
The production by cancer cells of glycolipids, perhaps derived partly from 
host glycolipids, may play essential roles in malignancy, tumor growth, 
immunity from host immunodefense, and metastasis. The glycolipids are 
derived from the primary glycolipid, glucosylceramide (GlcCerl, which is 
formed enzymatically from ceramide and uridine diphosphoglucose KJDP-glul. 
Injection of an inhibitor of this enzyme into mice bearing intraperitoneal 
Ehrlich ascites tumor cells (EATC) resulted in complete cure of about 30%1 of 
the mice and marked prolongation of life in the remainder. Almost all of the 
surviving mice were immune to a second inoculation of EATC. Injection of 
GlcCer stimulated cancer cell growth about 50% but this was largely reversed 
by the inhibitor. This type of inhibitor may have wide application to cancer 
chemotherapy. 
INTRODUCTION 
The glycosphingolipids of cancer cells may play essential roles in malignancy 
[1,2], tumor growth [3], immunity from host immunodefense [4], and metastasis 
[5]. Novel glycolipids have been isolated from cancerous cells [6--8) and some 
human tumors (melanomas1 have been killed by the injection of antibodies made 
to react with a specific glycolipid, ganglioside GD3 [9,10]. These glycolipids are 
made by glycosylation of the. primary glycolipid, GlcCer, which is formed 
enzymatically from ceramide and UDP-glu. Patients with Gaucher disease, a 
genetic disorder marked by deficient GlcCer glucosidase activity and 
accumulation of GlcCer, seem to have an unexpectedly high incidence of 
*Present address: Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma 8-19-1, 
Jonan-ku, Fukuoka 814-01, Japan. 
Address correspondence to Dr. N. Radin 
0304-3835/871$03.50 0 1987 Elsevier Scientific Publishers Ireland Ltd. 
Printed and Published in Ireland 
24 
leukemia and other disorders of B-cell proliferation [ll,lZ]. The suggestion has 
been offered that the high content of tissue GlcCer somehow overstimulates B- 
cell proliferation with consequent malignant or benign transformation. 
Gaucher patients not only accumulate large amounts of the lipid, but also 
suffer from severe hypertrophy of the spleen and liver. We have found [13] that 
injecting young mice with emulsified GlcCer causes liver uptake of the GlcCer 
and rapid growth of the liver, up to 37% in 1 day. The growth is accompanied 
by increased formation of DNA, lipid, and protein. The effect is stronger when 
conduritol B epoxide, which blocks the catabolism of GlcCer. is included with 
the glycolipid. 
On the basis of the many reports of this sort, one may hypothesize that 
tumors are more sensitive than hosts to interference with glyeolipid synthesis, 
transport, or metabolic functions. Recently we developed an optically active 
form (Dthreo) of 1-phenyl-2decanoylamino3-morpholinol-propanol (PDMP, 
Fig. 11, which inhibits UDP-glu:ceramide glucosyltransferase [14]. Injection of 
PDMP into mice bearing intraperitoneal EATC, as described in the present 
paper, resulted in substantial cure. By contrast, injected GlcCer stimulated 
EATC growth about 50% but the cells’ growth was largely reversed by the 
inhibitor. This type of inhibitor may have wide application to cancer 
chemotherapy. 
MATERIALS AND METHODS 
Animals and treatment. Male mice of the ICR (Swiss Hsdl strain from 
Harlan-Sprague Dawley (Indianapolis, IN), were injected i.p. with saline 
containing 2 x lo6 EATC on day 0. Each cage contained 5 mice which had been 
weight matched for similar means (25 gl and similar standard deviations by a 
computer program [15]. Treatment began 24 h later with i.p. injections of saline 
or PDMP acetate salt, dissolved in 40°C saline and injected at 10 g/g body wt. 
Ten animals were. assigned to each control or experimental group and fed 
Stearoyl sphingosine: 3 2 1 
cH3-(CHa)iz-CH=CH-CH(OH)-CH(NH-stearoyl)-CHsOH 




Fig. 1. Schematic structures of ceramide (the stearoyl isomer) and of PDMP. Because of the 
different numbering systems, carbon-l of the inhibitor is equivalent to carbon-3 of the natural lipid. 
25 
standard laboratory chow. In almost all cases the mice were injected daily for a 
total of 10 doses. 
UDP-glu : cemmide glucosyltmnsfem8e assay. Microsomes as source of 
enzyme were prepared by highspeed centrifugation and stored at - 70°C 
before use. The incubations were at 37OC for 30 min with microsomes, ATP, 
liposomal octanoyl sphingosine, UDP-(8Hlglu. Me, and dithioerythritol[16]. 
Cerebroside emulsions. Injectable suspensions of GlcCer and galactosyl- 
ceramide (GalCerl were prepared by mechanical grinding in saline (10 mglmll 
and injected at a dosage of 100 mg/kg. 
Statistics. The l-tailed Student’s t-test for unpaired samples was used. 
RESULTS 
The saline injected controls consistently showed rapid formation of EATC 
and ascites fluid, with markedly distended abdomens (median survival 24 days). 
About 30% of the mice treated with PDMP were apparently completely cured 
(Table 1). They showed no signs of ascites fluid formation at any time and at all 
times (> 10 months now for the first group) looked healthy although weight gain 
was temporarily slow or negative. The remaining mice died from a solid tumor 
version of the cells, but somewhat later than the untreated mice. The median T/ 
C ratios for the drug were 191%, 233%. 319% and 150% for the 4 experiments 
shown, well above the accepted minimal values for a ‘highly promising’ 
antineoplastic agent. 
A dose response test with 10 daily injections of PDMP (not listed) showed 
that the T/C index increased with increasing dosage, as did the percentage of 
total cure. All animals injected with 25 or 50 mg/kg died at about the same time 
TABLE 1 
ANTITUMOR ACTIVITY OF PDMP (ACETATE SALT) IN MICE 
Column a indicates the low drug toxicity. Column b, which shows the change in mean body weight at 
the end of 10 days, indicates the drug toxicity as evidenced by subnormal weight gain. Normal, 
uninoculated mice gain about 4.5 g during this period. The weight gain by control mice is largely due 
to growth of EATC. Columns c show the number of cured mice in parentheses; the other numbers 
include cured mice + mice bearing a solid tumor. 
Dosage 
(mg/kg per day) 
Surviving Body wt. 
at 10 days change 
(a) (b) 
Surviving 
at 60 days 
(c) 
Surviving 
at 90 days 
(c) 
Saline controls lO/lO + 10.9 g 0 
1 x lOO,daysl-10 10110 + 1.62 7 (4) 
2 x lOO,daysl-5 lO/lO + 3.78 5 (3) 
1 x 15O,daysl-10 lO/lO - 0.36 7 (3) 
2 x 150,days 1-5, 
1 x 150, days 6- 10 31’9 - 3.49 5 (3) 








TOXICITY TEST WITH PDMP INJECTED 10 TIMES AT 100 mg/kg per DAY 
The data represent means and standard deviations. The initial mean body weights were 24.4 g. 
Body wt. (8) 
Liver wt. @ 
Liver wt. (% of body) 
Kidney wt. (g) 
Kidney wt. (96 of body) 
Brain wt. (g) 
Brain wt. (% of body) 
Spleen weight(g) 
Spleen wt. (% of body) 
Controls 
28.8 f 1.4 
1.61 f 0.11 
5.57 f 0.24 
0.394 f 0.045 
1.87 f 0.11 
0.465 it 0.025 
1.61 f 0.08 
0.099 f 0.018 
0.34 f 0.06 
26.5 f 1.2** 
1.82 zt 0.12** 
4.97 f 0.52*+ 
0.329 f 0.027++ 
1.24 f 0.13. 
0.444 f o.ow 
1.67 f 0.08 
0.095 f 0.019 
0.36 f 0.07 
l P < 0.026, l *P < 0.05. 
as the controls, although the drug reduced the chance of early death. The 
percentages surviving for 60 days were lo%, 20% and 50% for 75,100 and 125 
mg/kg respectively. 
As a test of toxicity we injected 10 normal, non-cancerous mice with PDMP 
daily for 10 days, then killed them 5 h later (Table 21. The 10 control mice gained 
an average of 4.5 g while the treated mice gained 2.1 g. The treated mice had 
distinctly smaller weights: 8% in bodies, 18W in livers, and 17O/b in kidneys. 
The spleens were slightly but not significantly smaller and the brains were 
4.6% smaller (P < 0.0251. Using the data for percent of body weight, to 
minimize the importance of general toxicity, we found that only the livers and 
kidneys were significantly smaller Cp < 0.051. The above decreases in organ size 
were in the direction expected from a diminished level of tissue GlcCer, since 
injection of the latter produced liver growth [13]. 
In order to observe less evanescent responses in a similar test, we killed the 
animals 40 h after the last injection following 12 daily injections. Here, of the 
absolute weights, only the kidneys were statistically different in treated mice, 
11% smaller (P < 0.051. Comparing the 40-h and 5-h experiments it seems likely 
that the liver weights renormalized faster than the kidneys, perhaps a 
reflection of faster glycolipid turnover. 
Cell counts made on orbital blood showed no abnormalities in RBC, WBC, 
differential monocytes, lymphocytes, eosinophiles, and neutrophils. This failure 
to harm the bone marrow and related systems compares favorably with the 
high toxicity of many antineoplastics. 
Evidence that GlcCer metabolism is a rate-limiting factor in EATC growth 
was obtained by injecting a suspension of GlcCer into one group of 10 mice 
inoculated 1 day earlier with EATC as before. In one experiment, the mice 
were killed 1 day after the last of 8 daily injections and the ascites cells were 
flushed out of the abdomen with buffered saline and washed. The saline- 
injected controls yielded 3.07 ml of packed, centrifuged cells (mean value per 
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mouse), while the GlcCer-injected mice yielded 4.68 ml, an increase of 52% (P < 
0.051. Cell counts with a hemacytometer showed a similar increase so it can be 
concluded that the cells increased in number rather than in size. Mice treated 
with PDMP and GlcCer yielded 1.57 ml of cells (a 66% decrease compared with 
the GlcCer cells). This statistically significant difference demonstrates the 
ability of PDMP to inhibit EATC growth even in the presence of GlcCer. It 
seems as though the rate of exogenous GlcCer uptake and utilization was not 
rapid enough to supply all the requirements of the EATC for this lipid. 
A similar experiment gave very similar results (Table 31. Here the 
treatments were begun 3 days after EATC inoculation, only 5 injections were 
given, and the mice were killed 1 day later. GalCer, a glycolipid similar to 
GlcCer, showed no stimulation of EATC growth. The two lipids are catabolized 
to ceramide, sphingosine, and fatty acid, but only the glueolipid is anabolized to 
gangliosides. It is important to note that the EATC absorbed both glycolipids, 
as shown by thin-layer chromatography. Normal mice injected with GlcCer did 
not show the formation of a significant number of free peritoneal cells. 
Further evidence that PDMP acts via its inhibition of GlcCer biosynthesis 
came from assay of glucosyltransferase. Microsomes from EATC (0.50 mg 
protein) required 20 fl PDMP to reduce the glucosyltransferase activity in 
half. The microsomes from normal liver (72 rg protein) required 5 FM PDMP. 
While the EATC enzyme seems to be less sensitive to the inhibitor, the 
intraperitoneal concentration of inhibitor is initially very high. The L- 
enantiomer of PDMP did not inhibit the EATC enzyme, as observed for normal 
mouse tissue [14]. 
Unexpectedly we found that glucosyltransferase specific activity in the 
microsomal fraction of the EATC (0.41 nmol/h per mg protein1 was only l/7 that 
of liver microsomes from normal ICR Swiss mice. Our tentative conclusion from 
this is that these cells obtain much of their GlcCer from the peritoneum. Thus 
the effectiveness of the drug can tentatively be ascribed to a blockage of GlcCer 
synthesis by the host’s cells. 
Tumors appear to secrete (‘shed’) glycolipids which protect them from the 
host’s immunosurveillance system, rendering them resistant to immunological 
TABLE 3 
GROWTH OF EHRLICH ASCITES CELLS IN VIVO IN THE PRESENCE OF CEREBROSIDES 
AND GLUCOSYLTRANSFERASE INHIBITOR 
Treatment Vol. of packed cells 
(ml/mouse) 
% of control 
Saline controls 2.72 f 0.95 100 
GlcCer (166 mg/kg) 4.13 zt 0.63 152** 
GalCer (100 mg/kg) 2.29 f 1.21 84 
GlcCer + PDMP (166 mglkg) 1.40 f 1.19 51’ 
PDMP 1.68 f 0.86 62* 
*P < 0.06 compared with controls. **P < 0.01 compared with controls. 
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defense [4,17]. If PDMP acts to reduce the EATC’s resistance to the host’s 
immunodefense system, one ought to find antibodies to EATC in treated mice. 
As a preliminary test of this hypothesis, we challenged 4 mice who had 
survived 63 days post-inoculation with another 2 x lo6 EATC. These mice 
showed no effects of the reinoculation for >8 months more. Five other 
survivors were challenged 135 and 100 days after inoculation and four of them 
developed no EATC for >5 months of observation. Mice of this age, like the 
younger ones, are readily attacked by EATC. We conclude that the mice have 
been, in effect, ‘live-cell vaccinated’ with EATC plus PDMP. 
Preliminary trials have been made in EATC mice with racemic mixtures of 
homologs of PDMP in which the decanoyl moiety was replaced with other 
unsubstituted saturated fatty acids. The hexanoyl and octanoyl homologs 
seemed to be inactive, while the longer chain homologs were able to 
protect the mice. Palmitoyl and stearoyl derivatives were somewhat more 
toxic; nevertheless the latter produced about 75% complete 
(asymptomaticl cure, as evaluated 96 days after inoculation. 
DISCUSSION 
A proliferation effect of a glycolipid, ganglioside GQlb, was observed in 
cultured neuroblastomas [3], consistent with our findings with GlcCer in mice 
[13] and EATC. A similar effect was seen in vivo with a ganglioside mixture and 
human and rat tumors which were transplanted into nude mice [18]. Since these 
lipids are enzymatically converted to GlcCer and the many other glycolipids, it 
is not yet clear which compound is responsible for the growth effects. Possibly 
it varies with the cell type. 
Data point to the need by some cancer cells to obtain much of their fatty acid 
[19], cholesterol [20], and L-asparagine from the host [21]. Tumors apparently 
secrete lipotrophic factors which stimulate the host to mobilize its stored fat, 
presumably for use by the tumor [22,23]. Glial cells of brain apparently cannot 
make GlcCer by synthesis and must obtain the lipid or a more-glycosylated 
glycolipid from adjacent sources [24]. A carrier protein which can transfer 
GlcCer and other glycolipids from cell to cell has been characterized [25,26]. 
Glycolipids are also transferred through the blood stream in combination with 
lipoproteins [27]. These observations support our suggestion that EATC 
obtains much of its GlcCer from the host. It is possible that tumor cells, as they 
die from lack of glycolipid due to PDMP treatment, transfer their remaining 
glycolipids to still-intact tumor cells. This possible complication could explain 
the growth stimulating action of dying or dead cancer cells on potent cancer 
cells [28]. 
The evidence mentioned above points to the need for urgent development of 
more and better inhibitors of glycolipid synthesis, membrane binding and 
transport. Hakomori, in a recent review of some relationships between 
glycolipids and cancer [l], pointed out that ‘The composition of . . . membranes 
changes dramatically with . . . the onset of cancer. Exploiting such changes 
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could lead to improved diagnosis and treatment of cancer.’ The use of inhibitors 
of glycolipid synthesis would seem to be one important method of exploitation. 
Our laboratory continues to develop variants on the PDMP structure and to 
test them with the other hinds of cancer that might be more predictive of 
efficacy in human use. 
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